BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned a consensus rating of “Hold” from the thirteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $9.71.

BCRX has been the subject of several research analyst reports. Piper Jaffray Companies reiterated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. ValuEngine upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, September 6th. J P Morgan Chase & Co increased their price objective on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 6th. Finally, Royal Bank Of Canada initiated coverage on BioCryst Pharmaceuticals in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 price objective for the company.

In other news, Director Fred E. Cohen sold 54,250 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares in the company, valued at $941,237.20. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CMO William P. Sheridan sold 64,310 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 23.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock valued at $2,801,000 after buying an additional 62,792 shares in the last quarter. Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 19.9% in the second quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after buying an additional 996,052 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at $660,000. RA Capital Management LLC increased its position in shares of BioCryst Pharmaceuticals by 47.9% in the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after buying an additional 1,672,447 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of BioCryst Pharmaceuticals by 49.9% in the third quarter. Swiss National Bank now owns 171,300 shares of the biotechnology company’s stock valued at $898,000 after buying an additional 57,000 shares in the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.

Shares of BioCryst Pharmaceuticals (BCRX) traded up $0.64 during midday trading on Monday, hitting $5.21. The company had a trading volume of 3,230,100 shares, compared to its average volume of 1,528,498. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. BioCryst Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). The firm had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period last year, the company earned ($0.16) earnings per share. sell-side analysts predict that BioCryst Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/biocryst-pharmaceuticals-inc-bcrx-given-consensus-recommendation-of-hold-by-brokerages.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.